| 1. |
Attanoos RL, Papagiannis A, Suttinont P, et al. Pulmonary giant cell carcinoma: pathological entity or morphological phenotype?. Histopathology, 1998, 32(3): 225-234.
|
| 2. |
蒋代凤, 陆应麟, 邱宗荫, 等. 肺巨细胞癌高低转移株转移能力差异相关分子研究. 中华肿瘤杂志, 2003, 25(6): 531-534.
|
| 3. |
王浩, 陈海蛟, 张夏英, 等. 人肺巨细胞癌高(95D)低(95C)转移株中细胞周期调控因子的表达水平与细胞增殖能力的关系. 中国癌症杂志, 2005, 15(4): 343-346.
|
| 4. |
Li X, Zhang ZH, Liu JH, et al. Molecular features of giant-cell carcinoma of the lung: a case report and literature review. Onco Targets Ther, 2018, 11: 751-756.
|
| 5. |
Laforga JB. Giant cell carcinoma of the lung. Report of a case with cytohistologic and clinical correlation. Acta Cytologica, 1999, 43(2): 263-267.
|
| 6. |
Vieira T, Girard N, Ung M, et al. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma. J Thorac Oncol, 2013, 8(12): 1574-1577.
|
| 7. |
Leone A, Graziano P, Gasbarra R, et al. Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer, 2011, 128(3): 732-735.
|
| 8. |
Tamura Y, Fujiwara Y, Yamamoto N, et al. Retrospective analysis of the efficacy of chemotherapy and molecular targeted therapy for advanced pulmonary pleomorphic carcinoma. BMC Res Notes, 2015, 8: 800.
|
| 9. |
Weng SS, Cao Y, Tang XJ, et al. Epidemiological features of lung giant cell carcinoma and therapy for patients with EGFR mutations based on case reports and the surveillance, epidemiology, and end results (SEER) database. Oncotarget, 2017, 8(15): 25323-25333.
|
| 10. |
Ushiki A, Koizumi T, Kobayashi N, et al. Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol, 2009, 39(4): 267-270.
|
| 11. |
Weissferdt A, Moran CA. Primary giant cell carcinomas of the lung: a clinicopathological and immunohistochemical analysis of seven cases. Histopathology, 2016, 68(5): 680-685.
|
| 12. |
江文洋, 付向宁, 廖永德. 肺巨细胞癌 6 例临床分析. 临床肺科杂志, 2012, 17(2): 358-359.
|
1/5
WeChat